Long Term Effects of AAV1/SERCA2a Gene Transfer in Patients with Severe Heart Failure: Analysis of Recurrent Cardiovascular Events and Mortality
Rationale: The Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID 1) study was a phase 1/phase 2 first-in-human clinical gene therapy trial using an AAV1 vector carrying the cardiac sarcoplasmic reticulum ATPase pump (AAV1/SERCA2a) in patients with advanced heart failure. The study explored potential benefits of therapy at 12 months, and results were previously reported.
Objective: To report long-term (3-year) clinical effects and transgene expression for the patients in CUPID 1.
Methods and Results: A total of 39 patients with advanced heart failure who were on stable, optimal heart failure therapy, were randomized to receive intracoronary infusion of AAV1/SERCA2a in 1 of 3 doses (low dose-6 x 1011 DNase Resistant Particles [DRP], middle dose-3 x 1012 DRP and high dose-1 x 1013 DRP) versus placebo. The following recurrent cardiovascular and terminal events were tracked over 3 years in all groups: myocardial infarction, worsening heart failure, heart failure-related hospitalization, ventricular assist device placement, cardiac transplantation and death. The number of cardiovascular events, including death, was highest in the placebo group, high but delayed in the low and mid dose groups and lowest in the high dose group. Evidence of long-term transgene presence was also observed in high dose patients. The risk of pre-specified recurrent cardiovascular events was reduced by 82% in the high dose versus placebo group, p=0.048. No safety concerns were noted during the 3-year follow-up.
Conclusions: Following a single intracoronary infusion of AAV1/SERCA2a in patients with advanced heart failure positive signals in terms of cardiovascular events persist for years.
- gene therapy
- congestive heart failure
- calcium cycling
- gene therapy
- gene transfer
- heart failure
- sarcoplasmic reticulum Ca2+-ATPase
- Received August 14, 2013.
- Revision received September 20, 2013.
- Accepted September 24, 2013.